Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz

NCT00001758 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00001758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Completed
Start date
November 30, 1997
Completion date
August 31, 2003
Enrollment
25
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection